D-0767-2022 Class I Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-0767-2022 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Mar 8, 2022 and is designated Class I. Reason for recall: Labeling: Label mix-up: Incorrect label placed on product. Shipper cases labeled Meclizine Hydrochloride Tablets contain bottles incorrectly labeled as PredniSONE Tablets. The tablets in the bottles… The recall status is terminated (terminated Nov 15, 2022). Affected quantity: 12,174 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 6, 2022
Initiation Date
Mar 8, 2022
Termination Date
Nov 15, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,174 bottles

Product description

Meclizine Hydrochloride Tablets USP, 12.5 mg, packaged in a case of 24 bottles (100-count bottle), Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, 21801, NDC 59746-122-06

Reason for recall

Labeling: Label mix-up: Incorrect label placed on product. Shipper cases labeled Meclizine Hydrochloride Tablets contain bottles incorrectly labeled as PredniSONE Tablets. The tablets in the bottles are Meclizine Hydrochloride

Distribution pattern

Product was distributed in Arkansas, Florida, North Carolina, South Carolina and Ohio.

Code information

Lot # 22P0036, Exp 12/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0767-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0767-2022. Report a data issue: hello@regdatalab.com.